Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

11.71
-0.6600-5.34%
Post-market: 11.800.0900+0.77%16:20 EDT
Volume:8.26M
Turnover:98.59M
Market Cap:1.64B
PE:-3.50
High:12.41
Open:12.08
Low:11.70
Close:12.37
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.37
T/O Rate:6.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.25
PE(LYR):-3.07

Loading ...

Intellia Therapeutics Initiated at Underweight by Barclays

Dow Jones
·
Yesterday

Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target

MT Newswires Live
·
Oct 06

Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today

TIPRANKS
·
Oct 06

Wells Fargo Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
Oct 05

Intellia Awards 44,450 Inducement RSUs to Eight New Employees Under 2024 Plan

Reuters
·
Oct 03

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 03

Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?

Simply Wall St.
·
Oct 01

Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics today

TIPRANKS
·
Oct 01

Tracking Cathie Wood: Continuously increasing positions in gene-editing leader Intellia, reducing holdings in Brera Holdings

Options & Short Sell
·
Sep 11

Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today

TIPRANKS
·
Sep 10

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Intellia Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating

MT Newswires Live
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Intellia Rises After FDA Grants Fast-Track Status to Its Treatment for Rare Disease

Reuters
·
Sep 08

Intellia Therapeutics Shares up 4.9% Premarket After FDA Accepts to Fast-Track Co's Treatment for a Rare Swelling Disorder

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics announces FDA acceptance of lonvo-z BLA

TIPRANKS
·
Sep 08

Intellia Says FDA Accepts Lonvo-Z BLA for Hereditary Angioedema, Grants Priority Review

Reuters
·
Sep 08

Intellia Therapeutics, - FDA Accepts Bla for Lonvo-Z and Grants Priority Review with Pdufa Date March 10, 2027

THOMSON REUTERS
·
Sep 08